Business Wire

CA-FORESCOUT

6.12.2023 07:02:34 CET | Business Wire | Press release

Share
Critical Infrastructure Still at High Risk: Forescout Research Spotlights 21 New Vulnerabilities

Forescout, a global cybersecurity leader, today released “SIERRA:21 – Living on the Edge,” an analysis of 21 newly discovered vulnerabilities within OT/IoT routers and open-source software components. The report — produced by Forescout Research – Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in critical infrastructure — emphasizes the continued risk to critical infrastructure and sheds light on possible mitigations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205915662/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sierra:21 Infographic (Source: Forescout)

“SIERRA:21 – Living on the Edge” features research into Sierra Wireless AirLink cellular routers and some of its open-source components, such as TinyXML and OpenNDS. Sierra Wireless routers are popular — an open database of Wi-Fi networks shows 245,000 networks worldwide running Sierra Wireless for a variety of applications. For example, Sierra Wireless routers are used for police vehicles connecting to a central network management system or to stream surveillance video, in manufacturing plants for industrial asset monitoring, in healthcare facilities providing temporary connectivity and to manage electric vehicle charging stations. The 21 new vulnerabilities have the potential to stop vital communications that could impact everyday life.

Read the blog: Forescout Vedere Labs discloses 21 new vulnerabilities affecting OT/IoT routers

Forescout Research further finds:

  • The attack surface is expansive with 86,000 vulnerable routers still exposed online. Less than 10% of these routers are confirmed to be patched against known previous vulnerabilities found since 2019.
  • Regions with the highest number of exposed devices includes:
    • 68,605 devices in The United States
    • 5,580 devices in Canada
    • 3,853 devices in Australia
    • 2,329 devices in France
    • 1,001 devices in Thailand
  • Among the 21 vulnerabilities, one has critical severity (CVSS score 9.6), nine have high severity and 11 have medium severity. These vulnerabilities allow attackers to steal credentials, take control of a router by injecting malicious code, persist on the device and use it as an initial access point into critical networks.
  • Patching can’t fix everything. 90 percent of devices exposing a specific management interface have reached end of life, meaning they cannot be further patched.
  • It’s an uphill battle to secure supply chain components. Open-source software elements continue to go unchecked and increase the attack surface of critical devices, leading to vulnerabilities that may be hard for organizations to track and mitigate.

“We are raising the alarm today because there remain thousands of OT/IoT devices representing an increased attack surface that requires attention,” advises Elisa Constante, VP of Research, Forescout Research – Vedere Labs. “Vulnerabilities impacting critical infrastructure are like an open window for bad actors in every community. State-sponsored actors are developing custom malware to use routers for persistence and espionage. Cybercriminals are also leveraging routers and related infrastructure for residential proxies and to recruit into botnets. Our discoveries reaffirm the need for heightened awareness of the OT/IoT edge devices that are so often neglected.”

Sierra Wireless and OpenDNS have issued patches for the identified vulnerabilities. TinyXML is an abandoned open source project, so the upstream vulnerabilities will not be fixed and must be addressed downstream.

For more information, download the full report, “SIERRA:21 – Living on the Edge,” now at https://www.forescout.com/resources/sierra21-vulnerabilities.

Additional Resources:

About Forescout

Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205915662/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye